project: cardiodx

CardioDX logo

Connect with a Sales Specialist


Product Pipeline: Cardiac Arrhythmia

CardioDx and leading cardiologists have conducted a prospective, multi-center clinical study in cardiac arrhythmia called DISCERN (Diagnostic Investigation of Sudden Cardiac Event Risk). The DISCERN study was designed to develop and validate a genomics-based noninvasive test that will help identify patients with heart failure that are at risk for sudden cardiac death (SCD). Cardiac arrhythmias are disturbances in normal heart electrical activity that change heart rhythm and cause a person’s heart to beat too fast, too slow, or irregularly. SCD from lethal ventricular arrhythmias is a leading cause of mortality, responsible for up to half a million deaths annually in the U.S. and for approximately half of all mortality in patients with heart failure.1-3 Establishing a person’s risk for severe arrhythmias before a life-threatening event occurs remains a significant medical challenge. A genomic test may provide cardiologists a decision-making tool that will identify patients who would benefit most from an implantable cardioverter defibrillator (ICD), a device that helps treat irregular heartbeats and may prevent SCD.

For more information about the DISCERN study, see

  1. Zheng ZJ, Croft JB, Giles WH, et al. Sudden Cardiac Death in the United States, 1989 to 1998. Circulation 2001;104(18):2158-63.
  2. AHRQ Research Activities, December 2002. Researchers examine the risk factors for sudden cardiac arrest and management of at-risk patients. Rockville, MD: Agency for Healthcare Research and Quality, Office of Healthcare Information.
  3. State-specific mortality from sudden cardiac death—United States, 1999. MMWR Morb Mortal Weekly Rep 2002;51(6);123–6.
  4. DISCERN trial. Clinical trial summary found at:, NCT00500708.